TAS-102 plus radiation before surgery for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding TAS-102 (a chemotherapy medicine) to radiation given before treatment improves outcomes for certain locally advanced rectal cancers. It may help by trying to shrink the tumor before the next steps of care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have biopsy-proven rectal adenocarcinoma (a type of rectal cancer).
- Your cancer stage must match one of these patterns: T3–4 with no lymph nodes or distant spread, or T1–4 with limited/allowed lymph node spread but no distant spread.
- Your tumor must have “proficient” DNA mismatch repair on lab testing (a mismatch-repair protein test done on your tumor).
- You are age 18 to 75, and your general functioning score is at least 70.
- The tumor is close to the anus: less than 12 cm from the lower edge of the tumor to the anal opening.
- You must not have prior rectal surgery, prior pelvic radiation, or prior chemotherapy for rectal cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a newer chemo pill (TAS-102) works better than the standard pill (capecitabine) when given before radiation and surgery for rectal cancer. It is for people with stage II or III rectal cancer that has certain high-risk features.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests a combination of immunotherapy (tislelizumab) and standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to help shrink or eliminate the tumor so surgery might be less invasive or not needed, allowing you to keep your rectum.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.